Literature DB >> 26057692

Intrinsic relative activities of κ opioid agonists in activating Gα proteins and internalizing receptor: Differences between human and mouse receptors.

Kelly M DiMattio1, Frederick J Ehlert2, Lee-Yuan Liu-Chen3.   

Abstract

Several investigators recently identified biased κ opioid receptor (KOP receptor) agonists. However, no comprehensive study of the functional selectivity of available KOP receptor agonists at the human and mouse KOP receptors (hKOP receptor and mKOP receptor, respectively) has been published. Here we examined the ability of over 20 KOP receptor agonists to activate G proteins and to internalize the receptor. Clonal neuro-2a mouse neuroblastoma (N2a) cells stably transfected with the hKOP receptor or mKOP receptor were used. We employed agonist-induced [(35)S]GTPγS binding and KOP receptor internalization as measures of activation of G protein and β-arrestin pathways, respectively. The method of Ehlert and colleagues was used to quantify intrinsic relative activities at G protein activation (RAi-G) and receptor internalization (RAi-I) and the degree of functional selectivity between the two [Log RAi-G - logRAi-I, RAi-G/RAi-I and bias factor]. The parameter, RAi, represents a relative estimate of agonist affinity for the active receptor state that elicits a given response. The endogenous ligand dynorphin A (1-17) was designated as the balanced ligand with a bias factor of 1. Interestingly, we found that there were species differences in functional selectivity. The most striking differences were for 12-epi-salvinorin A, U69,593, and ICI-199,441. 12-Epi-salvinorin A was highly internalization-biased at the mKOP receptor, but apparently G protein-biased at hKOP receptor. U69,593 was much more internalization-biased at mKOP receptor than hKOP receptor. ICI199,441 showed internalization-biased at the mKOP receptor and G protein-biased at the hKOP receptor. Possible mechanisms for the observed species differences are discussed.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Kappa opioid receptor; Ligand bias; Species difference

Mesh:

Substances:

Year:  2015        PMID: 26057692      PMCID: PMC4532598          DOI: 10.1016/j.ejphar.2015.05.054

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  38 in total

Review 1.  Transduction of receptor signals by beta-arrestins.

Authors:  Robert J Lefkowitz; Sudha K Shenoy
Journal:  Science       Date:  2005-04-22       Impact factor: 47.728

2.  Psychotomimesis mediated by kappa opiate receptors.

Authors:  A Pfeiffer; V Brantl; A Herz; H M Emrich
Journal:  Science       Date:  1986-08-15       Impact factor: 47.728

Review 3.  Novel GPCR paradigms at the μ-opioid receptor.

Authors:  G L Thompson; E Kelly; A Christopoulos; M Canals
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 4.  Pharmacology of opioids.

Authors:  W R Martin
Journal:  Pharmacol Rev       Date:  1983-12       Impact factor: 25.468

5.  A kappa opioid effect: increased urination in the rat.

Authors:  J D Leander
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

6.  Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.

Authors:  J Zhu; L Y Luo; J G Li; C Chen; L Y Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  1997-08       Impact factor: 4.030

Review 7.  Physiological concentrations of purines and pyrimidines.

Authors:  T W Traut
Journal:  Mol Cell Biochem       Date:  1994-11-09       Impact factor: 3.396

8.  Studies on the nature and mechanism of the diuretic activity of the opioid analgesic ethylketocyclazocine.

Authors:  G R Slizgi; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1982-03       Impact factor: 4.030

9.  U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.

Authors:  P F Vonvoigtlander; R A Lahti; J H Ludens
Journal:  J Pharmacol Exp Ther       Date:  1983-01       Impact factor: 4.030

10.  Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.

Authors:  Yulin Wang; Kang Tang; Saadet Inan; Daniel Siebert; Ulrike Holzgrabe; David Y W Lee; Peng Huang; Jian-Guo Li; Alan Cowan; Lee-Yuan Liu-Chen
Journal:  J Pharmacol Exp Ther       Date:  2004-09-21       Impact factor: 4.030

View more
  16 in total

1.  Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity.

Authors:  Achla Gupta; Ivone Gomes; Erin N Bobeck; Amanda K Fakira; Nicholas P Massaro; Indrajeet Sharma; Adrien Cavé; Heidi E Hamm; Joseph Parello; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-09       Impact factor: 11.205

2.  Modulation of serotonin transporter function by kappa-opioid receptor ligands.

Authors:  Santhanalakshmi Sundaramurthy; Balasubramaniam Annamalai; Devadoss J Samuvel; Toni S Shippenberg; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  Neuropharmacology       Date:  2016-10-12       Impact factor: 5.250

Review 3.  A review of salvinorin analogs and their kappa-opioid receptor activity.

Authors:  Jeremy J Roach; Ryan A Shenvi
Journal:  Bioorg Med Chem Lett       Date:  2018-03-12       Impact factor: 2.823

4.  The C-2 derivatives of salvinorin A, ethoxymethyl ether Sal B and β-tetrahydropyran Sal B, have anti-cocaine properties with minimal side effects.

Authors:  Amy W M Ewald; Peter J Bosch; Aimee Culverhouse; Rachel Saylor Crowley; Benjamin Neuenswander; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Psychopharmacology (Berl)       Date:  2017-05-23       Impact factor: 4.530

5.  Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.

Authors:  Matthew L Lazenka; Megan J Moerke; E Andrew Townsend; Kevin B Freeman; F Ivy Carroll; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

Review 6.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

7.  Determination of sites of U50,488H-promoted phosphorylation of the mouse κ opioid receptor (KOPR): disconnect between KOPR phosphorylation and internalization.

Authors:  Chongguang Chen; Yi-Ting Chiu; Wenman Wu; Peng Huang; Anika Mann; Stefan Schulz; Lee-Yuan Liu-Chen
Journal:  Biochem J       Date:  2015-12-03       Impact factor: 3.857

Review 8.  An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects.

Authors:  Alexander R French; Richard M van Rijn
Journal:  Pharmacol Res       Date:  2022-01-29       Impact factor: 7.658

9.  Comparison of Pharmacological Properties between the Kappa Opioid Receptor Agonist Nalfurafine and 42B, Its 3-Dehydroxy Analogue: Disconnect between in Vitro Agonist Bias and in Vivo Pharmacological Effects.

Authors:  Danni Cao; Peng Huang; Yi-Ting Chiu; Chongguang Chen; Huiqun Wang; Mengchu Li; Yi Zheng; Frederick J Ehlert; Yan Zhang; Lee-Yuan Liu-Chen
Journal:  ACS Chem Neurosci       Date:  2020-09-24       Impact factor: 4.418

Review 10.  Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide.

Authors:  Soumen Chakraborty; Susruta Majumdar
Journal:  Biochemistry       Date:  2020-09-22       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.